The DNA-binding assay for NF-κB in nuclear extracts from tumor samples showed that TQ in combination with bortezomib significantly suppressed NF-κB activation, while TQ alone and bortezomib alone had much lesser inhibition on NF-κB than the drug combination (Fig. 6A). Here, NFKB1 is linked to neoplasm.